Calabresi, Laura; Carretta, Chiara; Romagnoli, Simone; Rotunno, Giada; Parenti, Sandra; Bertesi, Matteo; Bartalucci, Niccolò; Rontauroli, Sebastiano; Chiereghin, Chiara; Castellano, Sara; Gentili, Giulia; Maccari, Chiara; Vanderwert, Fiorenza; Mannelli, Francesco; Della Porta, Matteo; Manfredini, Rossella; Vannucchi, Alessandro Maria; Guglielmelli, Paola (2023). Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms. AMERICAN JOURNAL OF HEMATOLOGY, vol. 98, pp. 1520-1531, ISSN:0361-8609 DOI  

  Romagnoli, Simone; Bartalucci, Niccolò; Vannucchi, Alessandro Maria (2023). Resolving complex structural variants via nanopore sequencing. FRONTIERS IN GENETICS, vol. 14, pp. 0-0, ISSN:1664-8021 DOI  

  Bianchi, Elisa; Rontauroli, Sebastiano; Tavernari, Lara; Mirabile, Margherita; Pedrazzi, Francesca; Genovese, Elena; Sartini, Stefano; Dall'Ora, Massimiliano; Grisendi, Giulia; Fabbiani, Luca; Maccaferri, Monica; Carretta, Chiara; Parenti, Sandra; Fantini, Sebastian; Bartalucci, Niccolò; Calabresi, Laura; Balliu, Manjola; Guglielmelli, Paola; Potenza, Leonardo; Tagliafico, Enrico; Losi, Lorena; Dominici, Massimo; Luppi, Mario; Vannucchi, Alessandro Maria; Manfredini, Rossella (2023). Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model. LEUKEMIA, pp. 1-12, ISSN:0887-6924 DOI   Accesso ONLINE all'editore

  Calabresi, Laura; Carretta, Chiara; Romagnoli, Simone; Rotunno, Giada; Parenti, Sandra; Bertesi, Matteo; Bartalucci, Niccolò; Rontauroli, Sebastiano; Chiereghin, Chiara; Castellano, Sara; Gentili, Giulia; Maccari, Chiara; Vanderwert, Fiorenza; Mannelli, Francesco; Della Porta, Matteo; Manfredini, Rossella; Vannucchi, Alessandro Maria; Guglielmelli, Paola (2023). Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms. AMERICAN JOURNAL OF HEMATOLOGY, vol. 98, pp. 1520-1531, ISSN:0361-8609 DOI  

  Gerds, Aaron T; Bartalucci, Niccolo; Assad, Albert; Yacoub, Abdulraheem (2022). Targeting the PI3K pathway in myeloproliferative neoplasms. EXPERT REVIEW OF ANTICANCER THERAPY, vol. 22, pp. 835-843, ISSN:1473-7140 DOI  

  Maria Elena Melica, Giulia Antonelli, Roberto Semeraro, Maria Lucia Angelotti, Gianmarco Lugli, Samuela Landini, Fiammetta Ravaglia, Gilda La Regina, Carolina Conte, Letizia De Chiara, Anna Julie Peired, Benedetta Mazzinghi, Marta Donati, Alice Molli, Stefanie Steiger, Alberto Magi, Niccolò Bartalucci, Valentina Raglianti,, Francesco Guzzi, Laura Maggi, Francesco Annunziato, Alexa Burger, Elena Lazzeri, Hans-Joachim Anders, Laura Lasagni, Paola Romagnani (2022). Differentiation of crescent-forming kidney progenitor cells into podocytes attenuates severe glomerulonephritis in mice. SCIENCE TRANSLATIONAL MEDICINE, pp. 0-0, ISSN:1946-6242

  Loscocco, Giuseppe G; Guglielmelli, Paola; Mannelli, Francesco; Mora, Barbara; Mannarelli, Carmela; Rotunno, Giada; Pancani, Fabiana; Maccari, Chiara; Bartalucci, Niccolò; Romagnoli, Simone; Coltro, Giacomo; Passamonti, Francesco; Vannucchi, Alessandro M (2022). SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates. AMERICAN JOURNAL OF HEMATOLOGY, vol. 97, pp. E347-E349, ISSN:0361-8609 DOI  

  Genovese, Elena; Mirabile, Margherita; Rontauroli, Sebastiano; Sartini, Stefano; Fantini, Sebastian; Tavernari, Lara; Maccaferri, Monica; Guglielmelli, Paola; Bianchi, Elisa; Parenti, Sandra; Carretta, Chiara; Mallia, Selene; Castellano, Sara; Colasante, Corrado; Balliu, Manjola; Bartalucci, Niccolò; Palmieri, Raffaele; Ottone, Tiziana; Mora, Barbara; Potenza, Leonardo; Passamonti, Francesco; Voso, Maria Teresa; Luppi, Mario; Vannucchi, Alessandro Maria; Tagliafico, Enrico; Manfredini, Rossella; On Behalf Of The Mynerva MYeloid NEoplasms Research Venture Airc, null (2022). The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis. ANTIOXIDANTS, vol. 11, pp. 1-15, ISSN:2076-3921 DOI  

  Guglielmelli, Paola; Coltro, Giacomo; Mannelli, Francesco; Rotunno, Giada; Loscocco, Giuseppe G; Mannarelli, Carmela; Maccari, Chiara; Paoli, Chiara; Romagnoli, Simone; Bartalucci, Niccolò; Vannucchi, Alessandro M (2022). ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera. BLOOD ADVANCES, vol. 6, pp. 2927-2931, ISSN:2473-9537 DOI  

  Guglielmelli P, Irushani Vanderwert F, Romagnoli S, Coltro G, Loscocco GG, Mannelli F, Calabresi L, Gentili G, Rotunno G, Bartalucci N, Boldrini V, Sant'Antonio E, Tarantino D, Pieraccioli M, Vannucchi AM (2022). Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis. In: American Society of Hematology (ASH) 2022, Blood, pp. 832-833. DOI  

  Loscocco, Giuseppe G; Guglielmelli, Paola; Mannelli, Francesco; Mora, Barbara; Mannarelli, Carmela; Rotunno, Giada; Pancani, Fabiana; Maccari, Chiara; Bartalucci, Niccolò; Romagnoli, Simone; Coltro, Giacomo; Passamonti, Francesco; Vannucchi, Alessandro M (2022). SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates. AMERICAN JOURNAL OF HEMATOLOGY, vol. 97, pp. 347-349, ISSN:1096-8652 DOI  

  Calabresi, Laura; Balliu, Manjola; Bartalucci, Niccolò (2022). Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells. In: Lorenzo Galluzzi. Methods in Cell Biology - Stem cells, pp. 81-109 Elsevier, ISBN:9780323900188., vol. 171: DOI  

  Balliu M.; Calabresi L.; Bartalucci N.; Romagnoli S.; Maggi L.; Manfredini R.; Lulli M.; Guglielmelli P.; Vannucchi A.M. (2021). Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs. BLOOD ADVANCES, vol. 5, pp. 2184-2195, ISSN:2473-9529 DOI  

  Romagnoli S.; Bartalucci N.; Gesullo F.; Balliu M.; Bonifacio S.; Fernandez A.G.L.; Mannelli F.; Bolognini D.; Pelo E.; Mecucci C.; Guglielmelli P.; Vannucchi A.M. (2021). Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2. BIOMARKER RESEARCH, vol. 9, pp. 83-86, ISSN:2050-7771 DOI  

  de Logu F.; Marini M.; Landini L.; de Araujo D.S.M.; Bartalucci N.; Trevisan G.; Bruno G.; Marangoni M.; Schmidt B.L.; Bunnett N.W.; Geppetti P.; Nassini R. (2021). Peripheral nerve resident macrophages and schwann cells mediate cancer-induced pain A C. CANCER RESEARCH, vol. 81, pp. 3387-3401, ISSN:0008-5472 DOI  

  Bartalucci N.; Romagnoli S.; Vannucchi A.M. (2021). A blood drop through the pore: nanopore sequencing in hematology. TRENDS IN GENETICS, pp. 1-15, ISSN:0168-9525 DOI  

  Bartalucci, Niccolò; Galluzzi, Lorenzo (2021). Philadelphia-negative myeloproliferative neoplasms: From origins to new perspectives. In: Niccolò Bartalucci / Lorenzo Galluzzi. Cella and Molecular aspects of MPN, pp. 9-20 Elsevier., vol. 365: DOI  

  Guglielmelli P.; Pacilli A.; Coltro G.; Mannelli F.; Mannelli L.; Contini E.; Rotunno G.; Bartalucci N.; Fiaccabrino S.; Sordi B.; Loscocco G.G.; Paoli C.; Vannucchi A.M. (2020). Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms. AMERICAN JOURNAL OF HEMATOLOGY, vol. 95, pp. E23-E26, ISSN:0361-8609 DOI  

  Coltro G.; Rotunno G.; Mannelli L.; Mannarelli C.; Fiaccabrino S.; Romagnoli S.; Bartalucci N.; Ravenda E.; Gelli E.; Sant'Antonio E.; Patnaik M.M.; Tefferi A.; Vannucchi A.M.; Guglielmelli P. (2020). RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. BLOOD ADVANCES, vol. 4, pp. 3677-3687, ISSN:2473-9529 DOI  

  Bartalucci N.; Guglielmelli P.; Vannucchi A.M. (2020). Polycythemia vera: the current status of preclinical models and therapeutic targets. EXPERT OPINION ON THERAPEUTIC TARGETS, vol. 24, pp. 615-628, ISSN:1472-8222 DOI  

  Bartalucci, N; Mannelli, F; Contini, E; Romagnoli, S; Gianfaldoni, G; Scappini, B; Pelo, E; Pancani, F; Magi, A; Bosi, A; Guglielmelli, P; Vannucchi, AM (2019). THIRD GENERATION SEQUENCING OF NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA: IMPLICATIONS FOR PROGNOSIS. In: HAEMATOLOGICA, FERRATA STORTI FOUNDATION, vol. 104, pp. 12-12.

  Paola Guglielmelli, MD PhD, Niccolò Bartalucci, PhDBSc, Elisa Contini, PhD, Giada Rotunno, PhD, Annalisa Pacilli, PhD, Simone Romagnoli, BSc, Lara Mannelli, MD, Francesco Mannelli, MD, Giacomo Coltro, MD, Alessandro Pancrazzi, PhD, Valentina Ariu, BSci, Sara Fiaccabrino, Roberto Semeraro, Alberto Magi, PhD, Carmela Mannarelli, PhD, Francesca Gesullo, BSci, Chiara Paoli, PhD, Alessandro M. Vannucchi, MD (2019). Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs). BLOOD, pp. 0-0, ISSN:0006-4971

  Magi, Alberto; Bolognini, Davide; Bartalucci, Niccoló; Mingrino, Alessandra; Semeraro, Roberto; Giovannini, Luna; Bonifacio, Stefania; Parrini, Daniela; Pelo, Elisabetta; Mannelli, Francesco; Guglielmelli, Paola; Vannucchi, Alessandro Maria (2019). Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data. BIOINFORMATICS, pp. 1-9, ISSN:1367-4803 DOI  

  Salati S.; Genovese E.; Carretta C.; Zini R.; Bartalucci N.; Prudente Z.; Pennucci V.; Ruberti S.; Rossi C.; Rontauroli S.; Enzo E.; Calabresi L.; Balliu M.; Mannarelli C.; Bianchi E.; Guglielmelli P.; Tagliafico E.; Vannucchi A.M.; Manfredini R. (2019). Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants. SCIENTIFIC REPORTS, vol. 9, pp. 10558-10571, ISSN:2045-2322 DOI   Accesso ONLINE all'editore

  Bartalucci, Niccolò; Romagnoli, Simone; Contini, Elisa; Marseglia, Giuseppina; Magi, Alberto; Guglielmelli, Paola; Pelo, Elisabetta; Vannucchi, Alessandro M (2019). Long Reads, Short Time: Feasibility of Prenatal Sample Karyotyping by Nanopore Genome Sequencing. CLINICAL CHEMISTRY, vol. 65, pp. 1605-1608-1608, ISSN:0009-9147 DOI  

  Bolognini D.; Bartalucci N.; Mingrino A.; Vannucchi A.M.; Magi A. (2019). NANOR: A user-friendly R package to analyze and compare nanopore sequencing data. PLOS ONE, vol. 14, pp. 1-12, ISSN:1932-6203 DOI   Accesso ONLINE all'editore

  De Vita D, Mei D, Rutigliano D, Bartalucci N, Cinnante CM, Parrini E, Dilena R, Guerrini R, (2018). Familial dominant epilepsy and mild pachgyria associated with a constitutional LIS1 mutation. AMERICAN JOURNAL OF MEDICAL GENETICS. PART A, vol. 176, pp. 2808-2812, ISSN:1552-4833 DOI   Accesso ONLINE all'editore

  Rossi C.; Zini R.; Rontauroli S.; Ruberti S.; Prudente Z.; Barbieri G.; Bianchi E.; Salati S.; Genovese E.; Bartalucci N.; Guglielmelli P.; Tagliafico E.; Rosti V.; Barosi G.; Vannucchi A.M.; Manfredini R. (2018). Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis. MOLECULAR ONCOLOGY, vol. 12, pp. 2102-2123, ISSN:1574-7891 DOI   Accesso ONLINE all'editore

  Tefferi, Ayalew; Guglielmelli, Paola; Nicolosi, Maura; Mannelli, Francesco; Mudireddy, Mythri; Bartalucci, Niccolo; Finke, Christy M; Lasho, Terra L; Hanson, Curtis A; Ketterling, Rhett P; Begna, Kebede H; Naseema Gangat, null; Pardanani, Animesh; Vannucchi, Alessandro M (2018). GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. LEUKEMIA, vol. 32, pp. 1631-1642, ISSN:1476-5551 DOI   Accesso ONLINE all'editore

  Pacilli A.; Rotunno G.; Mannarelli C.; Fanelli T.; Pancrazzi A.; Contini E.; Mannelli F.; Gesullo F.; Bartalucci N.; Fattori G.C.; Paoli C.; Vannucchi A.M.; Guglielmelli P. (2018). Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea. BLOOD CANCER JOURNAL, vol. 8, pp. 122-131, ISSN:2044-5385 DOI   Accesso ONLINE all'editore

  Ruberti, S; Bianchi, E; Guglielmelli, P; Rontauroli, S; Barbieri, G; Tavernari, L; Fanelli, T; Norfo, R; Pennucci, V; G. Corbizi, Fattori; Mannarelli, C; Bartalucci, N; Mora, B; Elli, L; Avanzini, M. A; Rossi, C; Salmoiraghi, S; Zini, R; Salati, S; Prudente, Z; Rosti, V; Passamonti, F; Rambaldi, A; Ferrari, S; Tagliafico, E; Vannucchi, A. M; Manfredini, R. (2017). Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients. LEUKEMIA, pp. 00-01, ISSN:0887-6924 DOI  

  Erba, Benedetta Gaia; Gruppi, Cristian; Corada, Monica; Pisati, Federica; Rosti, Vittorio; Bartalucci, Niccoloâ ; Villeval, Jean-Luc; Vannucchi, Alessandro Maria; Barosi, Giovanni; Balduini, Alessandra; Dejana, Elisabetta (2017). Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis. THE AMERICAN JOURNAL OF PATHOLOGY, vol. 187, pp. 1879-1892, ISSN:0002-9440 DOI   Accesso ONLINE all'editore

  Bartalucci, Niccolã²; Calabresi, Laura; Balliu, Manjola; Martinelli, Serena; Rossi, Maria Caterina; Villeval, Jean Luc; Annunziato, Francesco; Guglielmelli, Paola; Vannucchi, Alessandro M. (2017). Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/ CIP2A axis. ONCOTARGET, vol. 8, pp. 96710-96724, ISSN:1949-2553 DOI   Accesso ONLINE all'editore

  Salati, Simona; Prudente, Zelia; Genovese, Elena; Pennucci, Valentina; Rontauroli, Sebastiano; Bartalucci, Niccolo'; Mannarelli, Carmela; Ruberti, Samantha; Zini, Roberta; Rossi, Chiara; Bianchi, Elisa; Guglielmelli, Paola; Tagliafico, Enrico; Vannucchi, Alessandro M; Manfredini, Rossella (2017). Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation. STEM CELLS AND DEVELOPMENT, pp. 00-01, ISSN:1547-3287 DOI  

  Sdan Verstovsek; Ben Y Zhang; Naseema Gangat; Francesco Passamonti; Domenica Caramazza; Barbara Mora; Margherita Maffioli; Paola Guglielmelli; Giada Rorunno; Annalisa Pacilli; Carmela Mannarelli; Holly L Geyer; Ruben A Mesa; Giovanni Barosi; Vittorio Rosti; Hans Carl Hasselbach; Kate J Newberry; Francisco Cervantes; Arturo Pereira; Alessandro M Vannucchi; Niccolò Bartalucci; Lisa Pieri; H Joachim Deeg; Olga Sala-Torra; Bart L Scott (2015). Novel insights into myelofibrosis pathophysiology and treatment. In: Sdan Verstovsek, Ben Y Zhang, Naseema Gangat, Francesco Passamonti, Domenica Caramazza, Barbara mora, Margherita Maffioli, Paola Guglielmelli, Giada Rorunno, Annalisa Pacilli, Carmela Mannarelli, Holly L Geyer, Ruben A Mesa, Giovanni Barosi, Vittorio Rosti, Hans Carl Hasselbach, Kate J Newberry, Francisco Cervantes, Arturo Pereira, Alessandro M Vannucchi, Niccolò Bartalucci, Lisa Pieri, H Joachim Deeg, Olga Sala-Torra, Bart L Scott. Novel Insights into Myelofibrosis Pathophysiology and Treatment, pp. 1-165 Future Medicine Ltd., ISBN:9781780845494. DOI   Accesso ONLINE all'editore

  Vannucchi, Alessandro M; Bartalucci, Niccolo; Pieri, Lisa; Guglielmelli, Paola (2015). Rationale for combination therapies in myelofibrosis. In: alessandro maria vannucchi, Niccolò bartalucci, Lisa Pieri, paola guglielmelli,. Novel Insights into Myelofibrosis Pathophysiology and Treatment, pp. 136-150 Future Medicine Ltd., ISBN:9781780845494. DOI   Accesso ONLINE all'editore

  Pardanani, A; Tefferi, A; Guglielmelli, P; Bogani, C; Bartalucci, N; Rodríguez, J; Extremera, S; Pérez, I; Alfaro, V; Vannucchi, A M (2015). Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial. BLOOD CANCER JOURNAL, vol. 5, pp. e286-e286, ISSN:2044-5385 DOI  

  Vannucchi AM;Rotunno G;Bartalucci N;Raugei G;Carrai V;Balliu M;Mannarelli C;Pacilli A;Calabresi L;Fjerza R;Pieri L;Bosi A;Manfredini R;Guglielmelli P (2014). Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value.. LEUKEMIA, vol. 28, pp. 1811-1818, ISSN:0887-6924 DOI  

  Vannucchi, A.M.; Rotunno, G.; Bartalucci, N.; Raugei, G.; Carrai, V.; Balliu, M.; Mannarelli, C.; Pacilli, A.; Calabresi, L.; Fjerza, R.; Pieri, L.; Bosi, A.; Manfredini, R.; Guglielmelli, P. (2014). Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value. LEUKEMIA, vol. 28, pp. 1811-1818, ISSN:0887-6924 DOI   Accesso ONLINE all'editore

  Guglielmelli P;Bartalucci N;Rotunno G;Vannucchi AM (2014). Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms.. EXPERT REVIEW OF HEMATOLOGY, vol. 7, pp. 423-425, ISSN:1747-4086 DOI  

  Bartalucci N;Tozzi L;Bogani C;Martinelli S;Rotunno G;Villeval JL;Vannucchi AM (2013). Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms.. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, vol. 17, pp. 1385-1396, ISSN:1582-1838 DOI  

  Bartalucci N;Guglielmelli P;Vannucchi AM (2013). Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 13 Suppl 2, pp. 307-309, ISSN:2152-2650 DOI  

  Bogani C;Bartalucci N;Martinelli S;Tozzi L;Guglielmelli P;Bosi A;Vannucchi AM. (2013). mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.. PLOS ONE, vol. 8, pp. e54826-e54826, ISSN:1932-6203 DOI  

  Alessandro M. Vannucchi; Costanza Bogani; Niccolò Bartalucci (2013). JAK PI3K/mTOR COMBINATION THERAPY. Numero: US20130040973 A1 Incyte Corp., Novartis Pharma AG

  Bartalucci N;Bogani C;Vannucchi AM (2013). Preclinical models for drug selection in myeloproliferative neoplasms.. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, vol. 8, pp. 317-324, ISSN:1558-8211 DOI  

  N. Bartalucci (2012). Studio della via di segnalazione Akt/mTOR nelle Neoplasie Mieloproliferative Croniche. (Tutor: A.M. Vannucchi)

  Guglielmelli, Paola; Barosi, Giovanni; Rambaldi, Alessandro; Marchioli, Roberto; Masciulli, Arianna; Tozzi, Lorenzo; Biamonte, Flavia; Bartalucci, Niccolò; Gattoni, Elisabetta; Lupo, Maria Letizia; Finazzi, Guido; Pancrazzi, Alessandro; Antonioli, Elisabetta; Susini, Maria Chiara; Pieri, Lisa; Malevolti, Elisa; Usala, Emilio; Occhini, Ubaldo; Grossi, Alberto; Caglio, Silvia; Paratore, Simona; Bosi, Alberto; Barbui, Tiziano; Vannucchi, Alessandro M (2011). Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. BLOOD, vol. 118, pp. 2069-2076, ISSN:0006-4971 DOI   Accesso ONLINE all'editore

  Antonioli E; Carobbio A; Pieri L; Pancrazzi A; Guglielmelli P; Delaini F; Ponziani V; Bartalucci N; Tozzi L; Bosi A; Rambaldi A; Barbui T; Vannucchi A (2010). Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia.. HAEMATOLOGICA, vol. 95, pp. 1435-1438, ISSN:0390-6078 DOI  

  L. Pieri ; C. Bogani ; P. Guglielmelli ; M. Zingariello ; RA. Rana ; N. Bartalucci ;A Bosi ; AM. Vannucchi (2009). The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera.. HAEMATOLOGICA, vol. 94, pp. 1537-1545, ISSN:0390-6078 DOI  

  Pieri L1; Bogani C; Guglielmelli P; Zingariello M; Rana RA; Bartalucci N; Bosi A; Vannucchi AM (2009). The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera.. HAEMATOLOGICA, pp. 1537-1545, ISSN:0390-6078

  V. Ponziani; F. Mannelli; N. Bartalucci; G. Gianfaldoni; F. Leoni; E. Antonioli; P. Guglielmelli; S. Ciolli; A. Bosi; A. M. Vannucchi (2008). No role for CXCL12-G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia.. LEUKEMIA, vol. 22, pp. 669-671, ISSN:0887-6924, Macmillan Magazines Limited:Porters South Crinian Street, London N1 9XW United Kingdom:011 44 207 8334000, 011 44 171 8434982, Fax: 011 44 207 812358: DOI